New HIV drug candidate passes first safety check in healthy volunteers
NCT ID NCT06012136
First seen Oct 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-stage study is testing the safety and tolerability of an experimental HIV treatment called a capsid inhibitor. It involves 85 healthy adults who receive one or more injections of the drug or a placebo. The goal is to see how the body handles the drug and whether it causes any side effects before moving to larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
-
GSK Investigational Site
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.